I hope but am not expecting anything significant. I feel confident that things are playing out as they should be. Just being there with Kaminsky speaks to our relationship with the foundation.
I like the fact that we are viewing the patients and their caregivers as valuable partners with reliable first hand insight instead of just test subjects.
I think Missling learned a tough lesson with his timelines. It was smart to push the Rett expectation back.
On a side note about partnerships/buyouts etc. Like many here, I’ve always asked myself. Where are the offers? Where are the BPs beating down our doors? Shouldn’t they be? Are we not on the radar?
I’ve realized and believe some have stated before. It is still way too early for that. We are on the radar. We are on the wait and see what happens radar list. Why would anyone partner/buy now while our science is not proven yet? If we get approved for Rett, our market cap could reach 1 billion pretty quickly.
Then we will be a target. And we would be a cheap acquisition that makes a tiny dent in their huge pocketbooks comparatively speaking. So why don’t we have offers? It’s not time and there’s no rush.
YET.
Like Missling said. Maybe we will revisit the blank check preferreds next year.
News 
Market Data 
Discover 
